drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, genetically engineered T cells expressing a chimeric antigen receptor targeting CD19 to deplete CD19+ B-lineage cells (B cells and plasmablasts) and reduce pathogenic anti–acetylcholine receptor autoantibodies in refractory AChR-positive myasthenia gravis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti‑CD19 chimeric antigen receptor bind and kill CD19+ B cells/plasmablasts via CAR‑triggered cytotoxicity, depleting B‑lineage cells and reducing pathogenic anti‑AChR autoantibodies in myasthenia gravis.
drug_name
CD19 CAR-T cells
nct_id_drug_ref
NCT05828225